Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Фаза 3
Идёт, набор закрыт
NCT01933932
| Заболевание | Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | AstraZeneca |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 510 участн. |
|---|
| Вмешательство | Selumetinib, Docetaxel, Pegylated G-CSF |
|---|
| Дата начала | 25.09.2013 |
|---|
| Дата завершения | 7.06.2016 |
|---|
| Публикация результатов | 29.08.2017 |
|---|
Кратко
The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor mutations of KRAS. This study will also assess the PK, safety, patient reported outcomes (PRO) and tolerability profile of the selumetinib/docetaxel combination, compared to placebo in combination with docetaxel
Progression-Free Survival (PFS)
Measured at baseline until the date of first documented objective disease progression. Estimated final completion : approximately 3 years after first subject in (FSI) · Months
| Selumetinib + Docetaxel | 3.9 Months |
|---|
| Placebo + Docetaxel | 2.8 Months |
|---|
| p-value | 0.4355 |
|---|
| Hazard Ratio (HR) | 0.93 (95% CI 0.77–1.12) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.